Gilead Sciences (GILD) Quarterly Report Leads to Morgan Stanley Reassessment

Morgan Stanley has reassessed its outlook for Gilead Sciences (GILD) following the company's recent quarterly report. GILD reported revenue of $6.36 billion for the last quarter, reflecting a year-over-year decrease of 4%. The company's earnings per share (EPS) were reported at $1.58, slightly below analysts' expectations of $1.60. This reassessment by Morgan Stanley could influence investor sentiment and GILD's stock performance in the near term.